Assessment of Lipid Levels and Dyslipidemia in Pediatric Patients with Congenital Heart Defects
By
Phillip S. Cheng
Jonathan A. Wheeler
Aaron T. Walsh
Chance R. Alvarado
Kan N. Hor
Andrew H. Tran
July 4, 2026
Clinical Scorecard: Assessment of Lipid Levels and Dyslipidemia in Pediatric Patients with Congenital Heart Defects
At a Glance
Category Detail
Condition Dyslipidemia in Pediatric Patients with Congenital Heart Defects Key Mechanisms Increased risk of atherosclerosis and cardiovascular disease due to dyslipidemia. Target Population Children aged 9-18 years with congenital heart defects. Care Setting Pediatric cardiology outpatient clinics.
Key Highlights
Dyslipidemia increases cardiovascular disease risk starting in childhood. AAP recommends lipid screening for children at ages 9-11 and 17-21. Only 18-31% of children with congenital heart disease underwent lipid screening. Lipid values in childhood can predict adult lipid levels. Low adherence to lipid screening guidelines among pediatricians. Guideline-Based Recommendations
Diagnosis
Lipid screening should be performed at ages 9-11 and 17-21 years. Management
Identify and treat dyslipidemia to reduce future cardiovascular risk. Monitoring & Follow-up
Regular follow-up lipid panels for children with congenital heart defects. Risks
Increased lifetime risk of cardiovascular disease in children with congenital heart defects. Patient & Prescribing Data
Children with congenital heart defects aged 9-18 years.
Limited data on dyslipidemia rates among screened children with congenital heart defects.
Clinical Best Practices
Ensure adherence to AAP lipid screening recommendations. Utilize electronic medical records for tracking lipid levels. Educate healthcare providers on the importance of early lipid screening. Related Resources & Content
